Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder.

One of these is the 5-HT2A receptor, which has a recently discovered unique characteristic: It dampens incoming visual information, giving our brain more space for internal processes and ...

We propose a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. A diverse sample with regard to ethnoracial identity and SES will be ...

According to the partners, DSP-0038 combines serotonin 5-HT2A receptor antagonism and 5-HT1A receptor agonism – two well established targets for antipsychotic drugs – in a single small molecule.

The Pacalis team is a blend of industry and academic expertise, led by co-founder and Monash university alumnus Dr David Bibby as Chief Executive Officer, and co-founder Professor Chris Langmead, ...